The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Trial in progress: A phase I study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction (G/GEJ) cancer.
 
Joseph Chao
Consulting or Advisory Role - Amgen; AstraZeneca (Inst); Boston Biomedical; Daiichi Sankyo; Foundation Medicine; Lilly; Macrogenics; Merck; Taiho Pharmaceutical
Speakers' Bureau - Merck
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst)
Travel, Accommodations, Expenses - Foundation Medicine; Macrogenics; Merck
 
Elvira Buxó
No Relationships to Disclose
 
Andrés Cervantes
Consulting or Advisory Role - Bayer; BeiGene; Merck Serono; Roche; SERVIER
Speakers' Bureau - Amgen; Bayer; Foundation Medicine; Merck Serono; Roche; SERVIER
Research Funding - Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck Serono (Inst); MSD (Inst); Roche (Inst); SERVIER (Inst)
 
Farshid Dayyani
Employment - Roche (I)
Consulting or Advisory Role - Array BioPharma; Eisai; Exelixis; Genentech/Roche
Speakers' Bureau - Amgen; Eisai; Exelixis; Genentech/Roche; ipsen; Sirtex Medical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); Merck (Inst)
 
Caio Max Sao Pedro Rocha Lima
Honoraria - Celgene; Eisai; Eisai; Taiho Pharmaceutical; Xcenda
Speakers' Bureau - Celgene; Eisai; Merck; Taiho Pharmaceutical
Research Funding - Boston Biomedical; Pharmacyclics; Rafael Pharmaceuticals
 
Richard Greil
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Merck; MSD; Novartis; Roche; Sandoz; Takeda
Consulting or Advisory Role - Abbvie; AstraZeneca; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen; Merck; MSD; Novartis; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Gilead Sciences (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Sandoz (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Bristol-Myers Squibb; Celgene; Gilead Sciences; Janssen-Cilag; MSD; Novartis; Roche
 
Hanneke W.M. Van Laarhoven
Honoraria - Lilly/ImClone
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Nordic Group; Servier
Research Funding - Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Nordic Group (Inst); Philips Healthcare (Inst); Roche (Inst); Servier (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Sylvie Lorenzen
No Relationships to Disclose
 
Volker Heinemann
Honoraria - Amgen; Baxalta; Boehringer Ingelheim; Celgene; Lilly; Merck; Roche; Sanofi; SERVIER; Sirtex Medical; Taiho Pharmaceutical
Consulting or Advisory Role - Amgen; Baxalta; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Halozyme; Merck; MSD; MSD Oncology; Roche; Sanofi; SERVIER; Sirtex Medical
Research Funding - Amgen (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Merck (Inst); Roche (Inst); Servier (Inst); Shire (Inst); Sirtex Medical (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; MSD; Roche; SERVIER; Shire; Sirtex Medical
 
Roman Kischel
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Patents, Royalties, Other Intellectual Property - Amgen
 
Kohei Shitara
Honoraria - Abbvie; Novartis; Yakult Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; Bristol-Myers Squibb; GlaxoSmithKline; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Mediscience Planning (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Sumitomo Group (Inst); Taiho Pharmaceutical (Inst)
 
Florian Lordick
Honoraria - AstraZeneca; BioNTech; Bristol-Myers Squibb; Elsevier; Infomedica; Lilly; Medscape; Merck KGaA; Merck Sharp & Dohme; Roche; SERVIER
Consulting or Advisory Role - Amgen; Astellas Pharma; Beigene; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; SERVIER; Zymeworks
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly